HORIZON-PFT
2007
Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly
In 7,765 postmenopausal women with osteoporosis, annual intravenous zoledronic acid 5 mg reduced new vertebral and hip fractures compared with placebo.
Result
Efficacy: New morphometric vertebral fractureRR 0.3 · P < 0.001
Below 1 favours annual intravenous zoledronic acid 5 mg, above 1 favours placebo.
Also reported: Hip fracture HR 0.59 (−41 %; p=0.002).
- Subtopic
- Intravenous bisphosphonate
- Design
- Double-blind RCT, 3 yr
- Relevance
- Important: one of several pillars.
- Source
- Black DM, et al. N Engl J Med. 2007;356(18):1809-1822.doi 10.1056/NEJMoa067312
Discussion & critique
Established annual intravenous bisphosphonate dosing, the option for patients intolerant of oral therapy or with adherence concerns.